Morgan Stanley Reiterates Overweight Rating on Johnson & Johnson (JNJ) Ahead of Single Shot Covid Vaccine Data
Tweet Send to a Friend
Morgan Stanley analyst David Lewis reiterated an Overweight rating and $178.00 price target on Johnson & Johnson (NYSE: JNJ) ahead ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
